English Overview
A medical webinar to address that patients do not receive accurate and/or timely clinical and biomarker diagnoses in the early
symptomatic stages of the AD continuum due to HCP’s limited understanding of the benefits
and limited access to relevant Dx tools.
This Activity for
- Resident / Fellow
- Physician
What I will learn?
Understanding the value of fluid biomarkers and how to implement them in clinical
routine for AD diagnosis pose barriers to the adoption of routine biomarker testing -
• What is the anticipated evolution of the patient journey?
• What are the hurdles and the potential solutions for Alzheimer's disease diagnosis?
• Considerations for Tau and amyloid CSF biomarker ratios: performance and interpretation
routine for AD diagnosis pose barriers to the adoption of routine biomarker testing -
• What is the anticipated evolution of the patient journey?
• What are the hurdles and the potential solutions for Alzheimer's disease diagnosis?
• Considerations for Tau and amyloid CSF biomarker ratios: performance and interpretation
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Clinical use of CSF biomarkers in a changing Alzheimer’s landscape Certificate
Certificate |
Certificate | Free |
VAT 15% Included
